Provided By PR Newswire
Last update: Jul 15, 2025
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIRâ„¢
Read more at prnewswire.com1.23
-0.05 (-3.91%)
1.71
-0.12 (-6.56%)
Find more stocks in the Stock Screener